BOLT Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bolt Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.77 |
| 52 Week High | US$1.94 |
| 52 Week Low | US$0.75 |
| Beta | 1.05 |
| 1 Month Change | -31.08% |
| 3 Month Change | -36.78% |
| 1 Year Change | -59.09% |
| 3 Year Change | -95.35% |
| 5 Year Change | n/a |
| Change since IPO | -97.62% |
Recent News & Updates
Recent updates
Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding
May 21
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01Bolt Biotherapeutics: A Promised Follow Up
Aug 26Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Aug 10We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Aug 18We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely
Aug 18Shareholder Returns
| BOLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.8% | 0.7% | 1.2% |
| 1Y | -59.1% | 5.0% | 27.7% |
Return vs Industry: BOLT underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: BOLT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| BOLT volatility | |
|---|---|
| BOLT Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BOLT's share price has been volatile over the past 3 months.
Volatility Over Time: BOLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Randy Schatzman | www.boltbio.com |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
Bolt Biotherapeutics, Inc. Fundamentals Summary
| BOLT fundamental statistics | |
|---|---|
| Market cap | US$29.55m |
| Earnings (TTM) | -US$63.03m |
| Revenue (TTM) | US$11.32m |
2.6x
P/S Ratio-0.5x
P/E RatioIs BOLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLT income statement (TTM) | |
|---|---|
| Revenue | US$11.32m |
| Cost of Revenue | US$61.54m |
| Gross Profit | -US$50.22m |
| Other Expenses | US$12.81m |
| Earnings | -US$63.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | -443.47% |
| Net Profit Margin | -556.59% |
| Debt/Equity Ratio | 0% |
How did BOLT perform over the long term?
See historical performance and comparison